FSG Impact Factor growth
Future Science Group (FSG) announced highlights of its latest journal Impact Factor results, with impressive results across its imprints Future Medicine and Expert Reviews, following the recent publication of the new Impact Factors in the 2008 Journal Citation Report (JCR) by Thomson Reuters. Impact Factors, calculated by Thomson Reuters indicate the number of times a published article has been cited during the course of a year – providing an indication on how much of an ‘impact’ a journals content is making on its research audience.
Across the Future Medicine and Expert Reviews portfolios there were considerable increases in Impact Factor, and the star performer was Nanomedicine with an impressive increase to 6.093 from 2.818 last year. Launched in 2006, Nanomedicine was selected for coverage in ISI® services and Medline at the earliest opportunity and was runner-up in the ALPSP Best New Journal category only one year after launch. The journal addresses basic research and clinical applications of nanotechnology, including nanomedical tools in gene therapy, drug delivery and commercialization and ethics of nanomedical technology. Senior Editors, Dr Charles Martin of the University of Florida and Dr Kostas Kostarelos of University of London were delighted at the jump in Impact factor. Dr Kostarelos said,
''The thrilling news that our journal and our field are gaining recognition and a wide readership can only make us proud. The sense of responsibility to maintain the highest standards of scientific quality generated in our laboratories and the need to contribute to clinical practice should be the main motivating forces from now on. We eventually need to place Nanomedicine among the pantheon of disciplines that helped transform clinical medicine.”
Pharmacogenomics (celebrating its 10th anniversary this year) was awarded a new Impact Factor of 3.551. The improved 2008 Impact Factors are testament to the fact that the Future Medicine & Expert Review journals are of high quality and widely read, and highly respected by researchers. The journals are now becoming a high priority for authors wishing to submit their important research findings and scientific opinions.
Editorial Director of FSG, Elisa Manzotti said,
“….the overall trend is up across all titles, and it is fantastic to see all of the Expert Reviews and Future Medicine titles enjoying a year on year increase. I’m also delighted to note that Nanomedicine took a massive leap in one year, which is a huge credit to the Senior Editors and their advisors, together with the many authors and referees who are committed to the title, and made the title such an unqualified success.”
Five titles in the Expert Review series and four Future Medicine publications had increased Impact Factors. In addition, a further two Future Medicine titles – Biomarkers in Medicine (launched in 2004) and Personalized Medicine – achieved their first Impact Factor in 2008 – an exciting development in light of the vast amount of research literature published each year.
Dr David Hughes, Publisher for the Future science Group, said,
“The Future Science Group portfolio brings a new and fresh approach to learned publishing, often addressing areas of science and medicine that are, as yet, in their infancy. It is very exciting, therefore, to see these titles becoming so well established in the journals firmament.”
The Future Science Group has an expending portfolio of innovative titles, with 2009 launches including Immunotherapy, Bioanalysis, Future Medicinal Chemistry, Interventional Cardiology, Imaging in Medicine, Epigenomics and Biofuels. Full information on all titles can be found at www.expert-reviews.com, www.futuremedicine.com and www.future-science.com. Free trials are available on request.
-- ENDS --
For further information please contact:
Craig Canham, Corporate Public Relations, Future Science Group
T: +44 (0) 20 8371 6092 F: +44 (0) 20 8343 2313 E: c.canham@futuremedicine.com
NOTES FOR EDITORS
About Nanomedicine
Nanomedicine (ISSN 1743-5889) covers the emerging scientific specialty born from nanotechnology, which has grown up in the fields of engineering, physics, chemistry and biotechnology, and is now moving into medicine, with huge potential for expansion and development over the next decade and beyond. The journal promises to be uniquely medicine-focused, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats, including reviews, primary research articles, technology reports, perspectives and editorials.
About Pharmacogenomics
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics focuses on those aspects that have the most direct relevance to the pharmaceutical industry and wider clinical community. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
About Biomarkers in Medicine
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
About Personalized Medicine
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review.
Journal Citation Report (Thomson Reuters, 2009)
All Impact Factors are taken from the 2008 Journal Citation Report, Science Edition (Thomson Reuters, 2009).
Thomson Reuters provide information about how Impact Factors are calculated here: scientific.thomson.com/free/essays/journalcitationreports/impactfactor/ and more detail on the
Journal Citation Report here: scientific.thomsonreuters.com/products/jcr/
Journal Citation Reports® (JCR) offers a systematic, objective means to critically evaluate the world's leading journals, with quantifiable, statistical information based on citation data. By compiling articles' cited references, JCR Web helps to measure research influence and impact at the journal and category levels, and shows the relationship between citing and cited journals.
The impact factors, which are calculated by ISI, look at citations in 2007 of articles published in the journals in the period 2005-2006.
About Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com
About Future Science Group
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. Through its imprints, Expert-Reviews, Future Medicine, and Future Science, the Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. For more information please access www.expert-reviews.com, www.futuremedicine.com, www.future-science.com and www.future-science-group.com